Please login to the form below

Not currently logged in

Synexus acquisition builds European reach

Synexus is to acquire ClinPharm, increasing its dedicated research centres to 26 in nine countries and significantly strengthening its presence in Europe

Synexus, the world's largest multi-national company dedicated to the recruitment and running of clinical trials at its own dedicated research centres, has agreed to acquire Leipzig-based ClinPharm, increasing the number of Synexus' dedicated research centres to 26 in nine countries and significantly strengthening its European reach.

While Synexus has a network of research centres in central and eastern Europe, the ClinPharm acquisition will add eight research centres in Germany. It will also strengthen Synexus' Central and Eastern Europe portfolio of centres in Poland, Hungary and Bulgaria, with additional sites in Austria and Ukraine.

The acquisition will also increase Synexus' total patient population reach to over 30 million patients; a rise of 50 per cent globally and 100 per cent across Europe. No other patient recruitment organisation can compete in terms of size or scale. ClinPharm also brings considerable additional therapy area experience to Synexus.

Commenting on the deal, Synexus chief executive, Michael Fort said: "Our work with some of the world's leading pharma companies has, however, now convinced the market that we do represent the new way of finding patients and running clinical trials at dedicated research centres. In order to keep pace with the market's demands, it is necessary for us to increase our infrastructure and patient reach.

"ClinPharm provided the ideal opportunity as they have considerable presence in Western, Central and Eastern Europe and also understand the way we work."

The deal will be finalised in January 2010 after ClinPharm's year end. ClinPharm's founding CEO, Hans-Detlev Stahl joins Synexus as European medical director.

Dr Stahl commented: "It was a natural fit to team up with Synexus. We know each other very well and our geographic coverage is totally complementary. Together we are much stronger and I look forward to helping the new company with further expansion which delivers real benefits to our clients in pharma."  

7th December 2009


Featured jobs

Subscribe to our email news alerts


Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...